Advances in site-specific gene editing for primary immune deficiencies

2018 ◽  
Vol 18 (6) ◽  
pp. 453-458 ◽  
Author(s):  
Caroline Y. Kuo
2021 ◽  
Author(s):  
Jihyun Park ◽  
Xiaohong Wang ◽  
Leonardo Mirandola ◽  
Maurizio Chiriva-Internati

2015 ◽  
Vol 169 (2) ◽  
pp. 931-945 ◽  
Author(s):  
Sergei Svitashev ◽  
Joshua K. Young ◽  
Christine Schwartz ◽  
Huirong Gao ◽  
S. Carl Falco ◽  
...  

2015 ◽  
Vol 23 ◽  
pp. S243
Author(s):  
Christos Georgiadis ◽  
Anastasia Petrova ◽  
John A. McGrath ◽  
Adrian J. Thrasher ◽  
Wei-Li Di ◽  
...  

2021 ◽  
Vol 53 (1) ◽  
pp. 29-54
Author(s):  
O. Kishchenko ◽  
◽  
A. Stepanenko ◽  
M. Borisjuk ◽  
◽  
...  

2016 ◽  
Vol 9 (1) ◽  
pp. 68-74
Author(s):  
Svetlana Kryštofová

AbstractTargeted genome editing using engineered nucleases such as ZFNs and TALENs has been rapidly replaced by the CRISPR/Cas9 (clustered, regulatory interspaced, short palindromic/ CRISPR-associated nuclease) system. CRISPR/Cas9 technology represents a significant improvement enabling a new level of targeting, efficiency and simplicity. Gene editing mediated by CRISPR/Cas9 has been recently used not only in bacteria but in many eukaryotic cells and organisms, from yeasts to mammals. Other modifications of the CRISPR-Cas9 system have been used to introduce heterologous domains to regulate gene expressions or label specific loci in various cell types. The review focuses not only on native CRISPR/Cas systems which evolved in prokaryotes as an endogenous adaptive defense mechanism against foreign DNA attacks, but also on the CRISPR/Cas9 adoption as a powerful tool for site-specific gene modifications in fungi, plants and mammals.


Cell Reports ◽  
2018 ◽  
Vol 23 (9) ◽  
pp. 2606-2616 ◽  
Author(s):  
Caroline Y. Kuo ◽  
Joseph D. Long ◽  
Beatriz Campo-Fernandez ◽  
Satiro de Oliveira ◽  
Aaron R. Cooper ◽  
...  

Molecules ◽  
2018 ◽  
Vol 23 (3) ◽  
pp. 632 ◽  
Author(s):  
Adele Ricciardi ◽  
Elias Quijano ◽  
Rachael Putman ◽  
W. Saltzman ◽  
Peter Glazer

Biology ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 530
Author(s):  
Marlo K. Thompson ◽  
Robert W. Sobol ◽  
Aishwarya Prakash

The earliest methods of genome editing, such as zinc-finger nucleases (ZFN) and transcription activator-like effector nucleases (TALENs), utilize customizable DNA-binding motifs to target the genome at specific loci. While these approaches provided sequence-specific gene-editing capacity, the laborious process of designing and synthesizing recombinant nucleases to recognize a specific target sequence, combined with limited target choices and poor editing efficiency, ultimately minimized the broad utility of these systems. The discovery of clustered regularly interspaced short palindromic repeat sequences (CRISPR) in Escherichia coli dates to 1987, yet it was another 20 years before CRISPR and the CRISPR-associated (Cas) proteins were identified as part of the microbial adaptive immune system, by targeting phage DNA, to fight bacteriophage reinfection. By 2013, CRISPR/Cas9 systems had been engineered to allow gene editing in mammalian cells. The ease of design, low cytotoxicity, and increased efficiency have made CRISPR/Cas9 and its related systems the designer nucleases of choice for many. In this review, we discuss the various CRISPR systems and their broad utility in genome manipulation. We will explore how CRISPR-controlled modifications have advanced our understanding of the mechanisms of genome stability, using the modulation of DNA repair genes as examples.


Sign in / Sign up

Export Citation Format

Share Document